In line with our data, preliminary clinical and molecular data from the Know Your Tumor (KYT) pancreas cancer program, which enables multiomic testing for DAC patients, suggests that low expression of SMAD4 and its target genes may contribute to FOLFIRINOX resistance [46,47]. Here, SMAD4 is linked to neoplasm.